However, Δ133p53β was significantly less frequently expressed in HER2 positive and luminal/HER2+ tumors than in other breast cancer subtypes (2/69, Fisher’s exact test, p≤0.042, Figure 1C). Here, ERBB2 is linked to breast carcinoma.